## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Mark Edward Bunnage, et :

al.

APPLICATION NO.: To Be Assigned : Examiner: To Be Assigned

FILING DATE: Herewith : Group Art Unit: To Be Assigned

TITLE: Novel Process For The Preparation of

Pyrazolopyrimidinones

Mail Stop Patent Applications Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

## <u>PURSUANT TO 37 C.F.R.</u> § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Respectfully submitted.

Date: Dec 1, 2003

James T. Jones
Attorney for Applicant(s)

Attorney for Applicant(s

Reg. No. 30,561

Pfizer Inc.
Patent Departm

Patent Department, MS 8260-1611 Eastern Point Road

Groton, Connecticut 06340

(860) 441-4903

INFORMATION DISCLOSURE CITATION ATTY. DOCKET NO									D. PC10384B SERIAL NO. To Be Assigned						d	
									rk Edward Bunnage, et al.							
Page 1 of 1 FILING DATE Here								ewith GROUP To Be Assigned								
						U.	S. PATEN	T DOC	JMENTS							
EXAMINER INITIAL			DOCUMENT NUMBER						DATE	NAME		CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
						FOR	EIGN PAT	ENT DO	CUMENTS					<del></del>		
DOCUMENT NUMBER							DATE	COUNTRY	<b>'</b>	CLASS	SUBCLASS	TRANS				
													_	YES	NO	
	wo	0	0	2	4	7	4	5	4 May 00	International		C07D_	487/04			
	wo	9	99	6	4	0	0	4	16 Dec 99	International		A61K	31/505			
	wo	0	1	2	2	9	1	8	5 April 01	International		A61K				
	wo	9	4	2	8	9	0	2	22 Dec 94	International		A61K	31/505			
	wo	9	8	5	4	3_	3	3	3 Dec 98	International		C12N	15/57			
	EP	0	8	11	2	8	4	5	17 Dec 97	EPO		C07D	487/04			
	EP	00	4	6	3	7	5	6	2 Jan 92	EPO		C07D	487/04			
	ĒΡ	0	9	1	6	6	7	5	19 May 99	EPO		C07D	487/04			
	DE	2	4	4	4	7	2	0	10 April 75	German		C07C	143-78	x		
			ОТН	ER DOC	UMEN	TS (/	ncluding A	uthor, T	itle, Date, Pe	ertinent Pa	ges, Et	c.)				
		XP002174403 Rotella, et al., J. Med. Chem. 2000, 43, pgs 1257-1263														
		XP002174404 Rotella, et al., J. Med. Chem, 2000, 43, pgs 5037-5043														
			<del></del>					· · · · · · · · · · · · · · · · · · ·	<del>.</del>	<del></del>				-		
			<del></del>					<u> </u>								
EXAMINER	₹							DATE C	ONSIDERED							
EXAMINER: In next communic	nitial if re cation to	eference cons applicant.	idered, whe	ether or not ci	tation is in c	onforma	nce with MPEP 6	09; Draw line	through citation if n	ot in conformance	and not co	nsidered. Ir	nclude copy of th	nis form w	rith	

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE